Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma

NCT01513187 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT01513187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01513187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 1/2
Overall status
Completed
Start date
July 11, 2011
Completion date
February 22, 2019
Enrollment
53 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma